Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
Page standards status: Informative |
{
"resourceType" : "Composition",
"id" : "399865",
"meta" : {
"versionId" : "2",
"lastUpdated" : "2025-09-14T18:14:16.995Z",
"profile" : [
"http://hl7.org/fhir/uv/pharmaceutical-research-protocol/StructureDefinition/m11-research-study-narratives"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Composition IGBJ-Narrative-1.3</b></p><a name=\"IGBJ-Narrative-1.3\"> </a><a name=\"hcIGBJ-Narrative-1.3\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-m11-research-study-narratives.html\">Research Study Narratives</a></p></div><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/uv/pharmaceutical-research-protocol/CodeSystem/narrative-elements-cs b001}\">Protocol narrative</span></p><p><b>date</b>: 2025-06-30 12:46:00+0000</p><p><b>author</b>: <a href=\"Organization-IGBJ-Organization.html\">Organization Eli Lilly Japan K.K</a></p><p><b>title</b>: IGBJ Protocol Narrative 1.3</p></div>"
},
"url" : "https://fevir.net/resources/Composition/399865",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net/FOI",
"value" : "399865",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/uv/pharmaceutical-research-protocol/CodeSystem/narrative-elements-cs",
"code" : "b001",
"display" : "Protocol narrative"
}
]
},
"subject" : [
{
🔗 "reference" : "ResearchStudy/399864",
"type" : "ResearchStudy",
"display" : "A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus (399864)"
}
],
"date" : "2025-09-14T18:14:16.995Z",
"author" : [
{
🔗 "reference" : "Organization/399869",
"type" : "Organization",
"display" : "Eli Lilly Japan K.K (399869)"
}
],
"title" : "IGBJ Protocol Narrative 1.3",
"custodian" : {
🔗 "reference" : "Organization/118079",
"type" : "Organization",
"display" : "Computable Publishing LLC"
},
"relatesTo" : [
{
"type" : "cite-as",
"targetMarkdown" : "IGBJ Protocol Narrative 1.3 [Database Entry: FHIR Composition Resource]. Contributors: Eli Lilly Japan K.K (399869) [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399865. Revised 2025-09-14. Available at: https://fevir.net/resources/Composition/399865. Computable resource at: https://fevir.net/resources/Composition/399865#json."
}
],
"section" : [
{
"title" : "1.3 Schedule of Activities",
"code" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C218519"
}
]
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">text describing SoA</div>"
}
}
]
}